MYCN and glioblastoma: In the pediatric GBM, among the three tumor subtypes classified by DNA methylation landscape (MYCN, RTK1, and RTK2), it was found that MYCN was enriched for MYCN amplification, RTK1 enriched for PDGFRA amplification, and RTK 2 enriched for EGFR amplification [64].